Inflammation as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction

Zhen Hui Peh; Adel Dihoum; Dana Hutton; J. Simon C. Arthur; Graham Rena; Faisel Khan; Chim C. Lang; Ify R. Mordi

doi:10.3389/fcvm.2023.1125687

Inflammation as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction

Zhen Hui Peh, Adel Dihoum, Dana Hutton, J. Simon C. Arthur, Graham Rena, Faisel Khan, Chim C. Lang, Ify R. Mordi (Lead / Corresponding author)

Cell Signalling and Immunology

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

207 Downloads (Pure)

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.

Original language	English
Article number	1125687
Number of pages	14
Journal	Frontiers in Cardiovascular Medicine
Volume	10
DOIs	https://doi.org/10.3389/fcvm.2023.1125687 https://doi.org/10.3389/fcvm.2023.1125687
Publication status	Published - 29 Jun 2023

Keywords

inflammation
heart failure
HFpEF
interleukins
cardiometabolic

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.3389/fcvm.2023.1125687Licence: CC BY
10.3389/fcvm.2023.1125687

Final Published VersionFinal published version, 36.5 MBLicence: CC BY

Cite this

@article{6efaca5742054a51a4f2accd50b09463,

title = "Inflammation as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction",

abstract = "Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.",

keywords = "inflammation, heart failure, HFpEF, interleukins, cardiometabolic",

author = "Peh, {Zhen Hui} and Adel Dihoum and Dana Hutton and Arthur, {J. Simon C.} and Graham Rena and Faisel Khan and Lang, {Chim C.} and Mordi, {Ify R.}",

note = "Funding Information: This work has been supported by a research grant from Tenovus Scotland (T20/58). Publisher Copyright: 2023 Peh, Dihoum, Hutton, Arthur, Rena, Khan, Lang and Mordi.",

year = "2023",

month = jun,

day = "29",

doi = "10.3389/fcvm.2023.1125687",

language = "English",

volume = "10",

}

TY - JOUR

T1 - Inflammation as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction

AU - Peh, Zhen Hui

AU - Dihoum, Adel

AU - Hutton, Dana

AU - Arthur, J. Simon C.

AU - Rena, Graham

AU - Khan, Faisel

AU - Lang, Chim C.

AU - Mordi, Ify R.

N1 - Funding Information: This work has been supported by a research grant from Tenovus Scotland (T20/58). Publisher Copyright: 2023 Peh, Dihoum, Hutton, Arthur, Rena, Khan, Lang and Mordi.

PY - 2023/6/29

Y1 - 2023/6/29

N2 - Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.

AB - Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.

KW - inflammation

KW - heart failure

KW - HFpEF

KW - interleukins

KW - cardiometabolic

UR - http://www.scopus.com/inward/record.url?scp=85164915905&partnerID=8YFLogxK

U2 - 10.3389/fcvm.2023.1125687

DO - 10.3389/fcvm.2023.1125687

M3 - Review article

C2 - 37456816

AN - SCOPUS:85164915905

SN - 2297-055X

VL - 10

JO - Frontiers in Cardiovascular Medicine

JF - Frontiers in Cardiovascular Medicine

M1 - 1125687

ER -

Inflammation as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Inflammation And Salt-Inducible Kinases - A Potential Novel Therapeutic Strategy In Patients With Heart Failure

Cite this

Inflammation as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Projects

Inflammation And Salt-Inducible Kinases - A Potential Novel Therapeutic Strategy In Patients With Heart Failure

Cite this